

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NEPTUNE GENERICS LLC,
Petitioner

v.

CORCEPT THERAPEUTICS, INC.
Patent Owner

Case IPR2018-01494
U.S. Patent No. 8,921,348

PETITIONER'S REPLY

TABLE OF CONTENTS

I. INTRODUCTION 1

II. CLAIM CONSTRUCTION 1

 A. Explicit Claim Constructions: “Method of Optimizing Levels of Mifepristone” and “Amenable to Treatment with Mifepristone” 1

 B. Implicit Claim Constructions: “To Achieve Blood Levels Greater than 1300 ng/mL” and “Disorder” 2

III. GROUND ONE 6

 A. The Board Improperly Focused Its Determination on Inherency 6

 B. Patent Owner’s Arguments Fail To Rebut Obviousness. 8

IV. GROUND TWO 10

 A. The Board Correctly Found That Belanoff 2002, Chu and Belanoff and Sitruk-Ware Together Render the Claims Obvious 10

 1. “A method for optimizing levels of mifepristone in a patient suffering from a disorder amenable to treatment by mifepristone” 10

 2. “treating the patient with seven or more daily doses of mifepristone” 11

 3. “testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL” 11

 4. “adjusting the daily dose of the patient...greater than 1300 ng/mL” 13

 B. Patent Owner’s Extraneous Evidence Fails To Rebut The Conclusion of Obviousness Claim. 14

 1. The pharmacokinetics (PK), pharmacodynamics (PD), and the PK/PD relationship for mifepristone was well-known at the time of invention. 15

2.	That mifepristone pharmacokinetics are non-linear, and vary from patient to patient, was both well-known and irrelevant. ..	16
3.	Distinguishing mifepristone blood level measurements from its metabolites was well-known in 2007.....	17
C.	There is a Motivation to Combine Belanoff 2002, Chu and Belanoff, and Sitruk-Ware.	17
D.	The Belanoff ‘348 “Invention” Was Not a “Breakthrough” Discovered After “Decades of Failure,” and No “More Efficient” Than the Prior Art.....	17
E.	In re Cyclobenzaprine is Inapposite Because it Involved a New Formulation.	21
V.	GROUND 3-6.....	22
VI.	CONCLUSION.....	23

TABLE OF AUTHORITIES

CASES

<i>A.C. Techs. S.A. v. Amazon.com, Inc.</i> , 912 F.3d 1358, 1366 (Fed. Cir. 2019)	4
<i>Andersen Corp. v. Fiber Composites, LLC</i> , 474 F.3d 1361 (Fed. Cir. 2007)	5
<i>Biomarin Pharmaceutical Inc. v. Genzyme Therapeutic Products Limited Partnership</i> , Case No. IPR2013-00534, 2015 WL 1009195 (Patent Tr. & App. Bd. Feb. 23, 2015)	9
<i>Glaxo Grp. Ltd. v. Apotex, Inc.</i> , 376 F.3d 1339 (Fed. Cir. 2004)	6
<i>In re Baxter Travenol Labs.</i> , 952 F.2d 388 (Fed. Cir. 1991)	9
<i>In re Boesch</i> , 617 F.2d 272 (C.C.P.A. 1980).....	9
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.</i> , 676 F.3d 1063 (Fed. Cir. 2012)	15, 21
<i>In re Ethicon, Inc.</i> , 844 F.3d 1344 (Fed. Cir. 2017)	7, 9
<i>In re Nuvasive, Inc.</i> , 842 F.3d 1376 (Fed. Cir. 2016)	3
<i>In re Prindle</i> , 297 F.2d 251 (C.C.P.A. 1962).....	9
<i>Luma Corp. v. Stryker Corp.</i> , 273 F. App'x 948 (Fed. Cir. 2008).....	4
<i>Pfizer, Inc. v. Teva Pharms. USA, Inc.</i> , 429 F.3d 1364 (Fed. Cir. 2005)	6
<i>Realtime Data, LLC v. Iancu</i> , 912 F.3d 1368 (Fed. Cir. 2019)	2

...

RPX Corp. v. Iridescent Networks, Inc.,
Case No. IPR2017-01661, Paper 29 (Patent Tr. & App. Bd.Dec. 10,
2018)3

Santarus, Inc. v. Par Pharmaceutical, Inc.,
694 F.3d 1344 (Fed. Cir. 2012)8

STATUTES

21 C.F.R. § 314.53(c)(2)(ii)(P)6

21 C.F.R. § 314.53(c)(2)(ii)(R).....6

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.